Attribution & Measurement
Why Pharma Attribution Is Broken.
You can't measure pharma marketing the way you measure e-commerce. There's no "Add to Cart" button for prescriptions. The path from campaign exposure to prescribing behavior crosses multiple touchpoints, multiple decision-makers, and a 90-180 day timeline. Here's how closed-loop measurement actually works in pharma.
NRx Lift Modeling
Connect marketing spend to new prescription volume.
Market Holdouts
Isolate channel impact through controlled market experiments.
Exposure → Outcome
Map the full path from impression to prescribing behavior.
Three Structural Barriers
These aren't technology gaps — they're fundamental differences in how pharma marketing works.
Last-Click Attribution Doesn't Exist in Pharma
A physician doesn't click a banner ad and immediately write a prescription. The pharma buying journey spans 90-180 days across multiple touchpoints: conference presentations, rep visits, peer-reviewed literature, DTC patient awareness, formulary committee decisions, and finally prescribing behavior. Measuring marketing impact with last-click models is like measuring rainfall by checking one bucket.
Data Lives in Incompatible Systems
Campaign exposure data lives in ad platforms. Rep activity data lives in Veeva CRM. Prescribing data lives in IQVIA or Symphony Health. Patient enrollment data lives in specialty pharmacy hubs. Each system uses different identifiers, different time granularity, and different data structures. Without a purpose-built integration layer, correlation is impossible.
Privacy Regulations Restrict Individual Tracking
HIPAA, state privacy laws, and platform restrictions prevent individual-level patient tracking. You can't connect a specific DTC impression to a specific patient's prescription. This means pharma measurement must work at the aggregate level — comparing exposed populations to control populations — which requires statistical methodology, not pixel tracking.
Closed-Loop Measurement Model
Five steps from campaign exposure to prescribing outcome — without individual-level tracking.
Exposure Mapping
Catalog every marketing touchpoint by channel, audience segment, geography, and time period. This includes DTC display/CTV impressions, HCP digital engagements, rep detailing calls, medical conference exposures, and endemic journal placements. Each touchpoint is tagged with audience classification (HCP vs. patient vs. caregiver) and compliance status.
Market-Level Holdout Design
Establish matched control markets where specific marketing channels are suppressed. This isn't random — markets are matched on baseline prescribing volume, competitive market share, formulary status, payer mix, and demographic composition. The holdout methodology allows you to isolate the incremental impact of each channel without individual-level tracking.
Prescribing Outcome Integration
Connect IQVIA or Symphony Health prescribing data (NRx, TRx, new-to-brand starts, market share) to the exposure and holdout framework. This creates the exposure → outcome link at the market level: markets with Campaign A running vs. matched markets without it, measured across 30/60/90/180-day windows to account for the pharma adoption cycle.
Incrementality Calculation
Calculate the incremental prescribing lift attributable to each marketing channel by comparing exposed markets to holdout markets, adjusting for confounding variables (seasonality, competitive launches, formulary changes, managed care decisions). The output: 'Channel X generated Y incremental NRx at $Z cost per incremental prescription.'
Optimization Loop
Feed incrementality data back into media planning and budget allocation. Shift spend toward channels with the highest incremental NRx per dollar, test new creative and messaging approaches in isolated markets, and continuously refine the holdout design based on learnings. This creates a measurement system that improves its own accuracy over time.
Metrics That Matter
What we measure — and why each one connects to business outcomes.
NRx Lift
Incremental new prescriptions in exposed vs. control markets
TRx Share
Total prescription market share change attributable to campaigns
New-to-Brand Starts
First-time prescribers entering the franchise
Cost per Incremental NRx
Marketing investment per additional new prescription
HCP Engagement Rate
Physician-level digital engagement depth and frequency
Time-to-First-Rx
Days from first marketing exposure to first prescription
Formulary Pull-Through
Prescribing lift in markets post-formulary approval
Patient Adherence Correlation
Refill rates in markets with vs. without adherence messaging
Common Questions
Start Measuring What Actually Matters
Request a measurement audit. We'll assess your current attribution methodology, identify gaps in your data infrastructure, and design a closed-loop model that connects marketing spend to prescribing outcomes.